Thursday, October 22, 2026

Unite Group Targets £300-400M Asset Sales as University Nomination Cuts Hit Margins

Unite Group plans £300-400 million in property disposals for 2026 after universities reduced nominated bed commitments by 1,000-2,000 units. The REIT maintains flat dividend guidance despite slower sales cycles and 2.4% rental growth at the low end of targets. Management is shifting portfolio mix toward high-tariff beds now at 67% of inventory.

Unite Group Targets £300-400M Asset Sales as University Nomination Cuts Hit Margins
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Unite Group announced £300-400 million in planned disposals for 2026 at expected yields of 5.5-6%, responding to margin pressure from reduced university nomination agreements. The student accommodation REIT faces a 1,000-2,000 bed reduction in university-nominated inventory for 2026, down from previous levels.

Current bookings stand at 68% of capacity, trailing typical sales pace as universities cut back nomination commitments. Rental growth for new bookings reached 2.4% on a revenue per occupied room (RevPOR) basis, landing at the lower bound of the company's 2-3% guidance range.

Unite Group set 2026 adjusted earnings per share guidance at 41.5-43 pence while holding its dividend flat year-over-year. The disposal program aims to recycle capital from lower-yielding assets into properties with stronger pricing power.

Management increased high-tariff bed exposure to 67% of the portfolio, targeting 80% medium-term. High-tariff properties command premium rents in tight supply markets near major universities. The portfolio rebalancing strategy addresses margin compression from the shift in university procurement patterns.

Nomination beds historically provided stable occupancy through bulk agreements with universities guaranteeing room blocks. The pullback in these commitments forces REITs to rely more on direct-to-student marketing, increasing operational costs and vacancy risk during slower booking periods.

The disposal program's 5.5-6% yield target suggests Unite is selling older or secondary market assets to fund acquisitions in core locations. Capital recycling at this scale represents roughly 8-10% of Unite's £4 billion-plus portfolio value based on recent valuations.

Student housing REITs face diverging performance based on nomination bed exposure and geographic concentration. Properties with high direct-let ratios in supply-constrained markets show more pricing flexibility than those dependent on institutional booking agreements.

Unite's margin compression coincides with broader UK higher education enrollment uncertainty amid visa policy changes and demographic shifts. The sector's ability to maintain rental growth while absorbing lower nomination volumes will determine valuation multiples through the current cycle.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com